To better explore the role of tau protein hyperphosphorylation in T2DM we used a therapeutic dose limit of 1 mmol/kg LiCl administered intraperitoneally to HFD-fed STZ-treated rats either daily or every other day for 14 weeks [27]. This evidence concerns the gene MAPT and type 2 diabetes mellitus.